POLE and endometrial carcinoma: Assuming an unbiased distribution and a POLE mutation prevalence of 10% in unselected endometrial carcinomas based on 12.2% reported in a large retrospective cohort, from which 82% are now considered pathogenic mutations [22, 23], we estimated that approximately 8/78 IR/HIR cases would harbor POLE mutations.